Neuroblastoma, a cancer of the developing nervous system, has long challenged researchers because its behavior can vary dramatically from one patient to another. Some tumors respond well to treatment, while others grow aggressively, spread rapidly, and return despite intensive therapy. A new study published in the British Journal of Cancer examines one of the most important genetic features associated with this disease: changes affecting the long arm of chromosome 17, known as 17q. The research presents chromosome 17q as more than a passive marker of cancer progression, describing it as a functional region where the demands of rapid DNA replication collide with the cell’s need to preserve genomic stability.

Chromosome 17q is frequently altered in neuroblastoma, particularly through the gain of additional genetic material. In cancer biology, such gains can increase the dosage of genes that support tumor growth, survival, or resistance to treatment. Yet the consequences are not necessarily uniform across the entire chromosome. A duplicated region may contain genes with opposing effects: some may help malignant cells divide, while others may create vulnerabilities by placing excessive pressure on the machinery responsible for copying DNA. The study by Hilgert, Depestel, Van Roy and colleagues investigates this functional complexity rather than treating 17q gain as a single, indivisible event.

DNA replication is the process by which a cell copies its genome before dividing. This operation must proceed rapidly but with remarkable accuracy. When replication forks—the molecular structures that move along DNA during copying—slow down, stall, or collapse, cells experience replication stress. Replication stress can arise when cancer cells divide too quickly, when DNA contains difficult-to-copy sequences, or when the supply of nucleotides and other replication components becomes insufficient. If unresolved, stalled replication forks can generate DNA breaks and rearrangements, helping tumors evolve while also threatening the survival of the cells that carry them.

The new work focuses on how genetic elements within 17q influence this balance. A region that promotes proliferation may simultaneously intensify replication stress, creating a biological paradox. Tumor cells benefit from increased growth signals, but they must also develop mechanisms to tolerate the resulting damage. This dependence can become a weakness: cancer cells operating close to the limits of replication may rely heavily on DNA repair pathways and checkpoint systems that normal cells use less intensively. Disrupting those support systems could selectively harm tumor cells, an idea that has become central to the development of targeted cancer treatments.

The researchers describe a “functional landscape” for chromosome 17q, suggesting that the region should be understood through the combined activity of its genes and regulatory elements. Genes do not act in isolation. Their effects depend on gene dosage, cellular context, interactions with other genomic regions, and the stage of tumor development. In neuroblastoma, these relationships may determine whether a 17q alteration produces a viable, treatment-resistant cancer cell or instead creates so much replication difficulty that the cell becomes vulnerable to damage and death. Mapping these relationships offers a more precise view of why the same broad chromosomal change can have different consequences in individual tumors.

This perspective is especially important because neuroblastoma often develops from immature cells of the peripheral nervous system. During early development, these cells naturally undergo tightly regulated programs of growth, migration, and differentiation. Cancer can emerge when those programs are disrupted, allowing cells to continue dividing instead of maturing into specialized nerve-related cells. Additional chromosomal alterations may then reinforce the malignant state. By connecting 17q abnormalities with replication stress and genome maintenance, the study places a major neuroblastoma feature within the wider biology of developmental cancer.

Genomic stability refers to the ability of a cell to copy and preserve its DNA without accumulating excessive mutations or structural changes. Cancer cells frequently compromise this stability, producing an unstable genome that can accelerate adaptation. However, instability has limits. Too little DNA damage may not generate enough diversity for a tumor to evolve, while too much can trigger cell death or permanent growth arrest. The study’s central concept is that 17q alterations may push neuroblastoma cells toward this dangerous threshold, forcing them to balance accelerated growth against the risk of catastrophic replication failure.

The findings could influence how researchers think about treatment strategy. If specific 17q-associated activities make tumor cells dependent on replication-stress responses, therapies aimed at DNA damage checkpoints or repair enzymes might be especially effective in selected neuroblastomas. Such approaches could potentially be combined with existing treatments, including chemotherapy, which already damages DNA but can also harm healthy tissues. The challenge will be identifying which tumors truly depend on particular repair mechanisms and determining how to target those dependencies without increasing toxicity. A functional map of 17q could help move treatment decisions beyond the simple presence or absence of a chromosomal gain.

The study also highlights why cancer genomes should not be interpreted solely through large-scale structural changes. A chromosomal gain may be clinically useful as a prognostic signal, but its biological meaning depends on the genes and pathways it affects. By examining how chromosome 17q contributes to replication stress and genome protection, the researchers provide a framework for understanding why this region is repeatedly selected during neuroblastoma evolution. Their work points toward a future in which genetic alterations are assessed not only as labels of risk, but as clues to the specific pressures that keep cancer cells alive—and the vulnerabilities that may ultimately bring them down.

Subject of Research: Functional effects of chromosome 17q alterations, replication stress, and genomic stability in neuroblastoma

Article Title: A functional landscape for chromosome 17q in neuroblastoma: balancing replication stress and genomic stability

Article References: Hilgert, E., Depestel, L., Van Roy, N. et al. “A functional landscape for chromosome 17q in neuroblastoma.” British Journal of Cancer (2026). https://doi.org/10.1038/s41416-026-03569-w

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03569-w

Keywords: Neuroblastoma, chromosome 17q, replication stress, genomic stability, DNA replication, DNA repair, cancer genetics, tumor evolution, developmental cancer

A new study published in the British Journal of Cancer is challenging the way lung-cancer risk is discussed among people who do not smoke conventional cigarettes. Researchers led by S. Vaja, J.L. Dickson and C. Horst examined the effects of cigar, cigarillo and pipe smoking, focusing on two questions with immediate public-health consequences: how these products influence the likelihood of developing lung cancer and whether their users are being identified as eligible for screening.

Lung-cancer prevention strategies have traditionally been built around cigarette consumption, especially the number of cigarette packs smoked per year. This measure, known as pack-years, combines smoking intensity and duration. One pack-year generally represents smoking 20 cigarettes a day for one year. Because cigars, cigarillos and pipes are used differently from cigarettes, their tobacco exposure is harder to convert into the same standardized measurement. That difference can leave regular users outside the systems designed to identify people at high risk.

The study addresses a persistent misconception: that alternative combustible tobacco products are inherently safer because they are not smoked in the same way as cigarettes. Cigar and pipe users may inhale less deeply or less frequently, but the smoke still contains carcinogenic compounds produced by burning tobacco. These include polycyclic aromatic hydrocarbons, tobacco-specific nitrosamines, volatile organic compounds and fine particulate matter. The precise dose entering the lungs can vary substantially, yet repeated exposure can still damage airway cells and contribute to mutations associated with cancer development.

Cigarillos occupy a particularly complicated position because they range from small, cigarette-like products to larger cigars that may be smoked over a longer period. Their nicotine content and smoke volume can also differ widely. Some users inhale cigarillo smoke deeply, while others do not. Pipes introduce another set of variables, including the duration of a smoking session, the amount of tobacco burned and the frequency with which the pipe is used. These differences make simple comparisons difficult, but they do not eliminate the biological hazards of combustion.

According to the research, the central concern is not only whether cigar, cigarillo and pipe smoking increases lung-cancer risk, but also whether current screening rules recognize that risk. Lung-cancer screening commonly relies on age and a history of cigarette smoking measured in pack-years. People who have smoked other combustible tobacco products may therefore be classified as having insufficient exposure, even when their cumulative tobacco use has been substantial. If risk is underestimated at the eligibility stage, some people could miss the opportunity to detect a tumour before symptoms appear.

Screening works by identifying disease at an earlier and more treatable stage, often using low-dose computed tomography, or LDCT. Unlike a conventional CT scan, LDCT uses a lower radiation dose to create detailed images of the lungs. Its effectiveness depends on selecting people whose probability of developing lung cancer is high enough to justify the benefits and potential harms of testing. Those harms include false-positive findings, unnecessary follow-up procedures, anxiety and cumulative radiation exposure. The challenge is to expand access without encouraging indiscriminate scanning.

The researchers’ analysis highlights why tobacco history needs to be recorded in greater detail. A questionnaire that asks only whether someone smokes cigarettes can overlook the frequency, duration and type of cigar, cigarillo or pipe use. It may also fail to capture former users whose exposure occurred years earlier. More comprehensive risk models could incorporate the number of products used, smoking intensity, years since quitting, inhalation patterns and additional factors such as age, occupational exposure, air pollution and family history.

The findings also carry a message for people who use these products socially or intermittently. Risk is not determined solely by whether smoking occurs every day. The biological impact depends on cumulative exposure, the composition of the product and how smoke is inhaled. Occasional use may carry less risk than heavy, long-term use, but “less” does not mean “none.” Combustible tobacco remains fundamentally different from non-combustible nicotine products because burning creates the toxic mixture responsible for much of the damage to the respiratory system.

The study does not suggest that every cigar or pipe smoker should automatically undergo a CT scan. Instead, it points to a gap between real-world tobacco exposure and the simplified categories used in many screening policies. The authors’ work could encourage clinicians and policymakers to assess alternative tobacco use more systematically and to investigate whether existing eligibility thresholds should be adapted. Any change would require careful validation, because screening recommendations must balance earlier diagnosis against the risks of testing people who are unlikely to benefit.

The broader lesson is that lung-cancer risk cannot be reduced to a single cigarette-based number. As smoking patterns evolve and tobacco products diversify, prevention programmes must keep pace with the ways people actually consume tobacco. The study by Vaja and colleagues adds evidence that cigar, cigarillo and pipe smoking deserve a more visible place in lung-health research and clinical risk assessment. For now, the clearest preventive message remains unchanged: avoiding all combustible tobacco products offers the strongest protection, while anyone with a history of substantial use should discuss their individual risk with a healthcare professional.

Subject of Research: The effects of cigar, cigarillo and pipe smoking on lung-cancer risk and eligibility for lung-cancer screening.

Article Title: The effect of cigar, cigarillo and pipe smoking on lung cancer risk and screening eligibility.

Article References: Vaja, S., Dickson, J.L., Horst, C. et al. “The effect of cigar, cigarillo and pipe smoking on lung cancer risk and screening eligibility.” British Journal of Cancer (2026). https://doi.org/10.1038/s41416-026-03578-9

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03578-9

Keywords: lung cancer, cigar smoking, cigarillo smoking, pipe smoking, tobacco exposure, cancer screening, low-dose CT, smoking-related cancer, public health, epidemiology

A new study is challenging one of the most persistent assumptions in space manufacturing: that building advanced composite structures beyond Earth is simply a matter of moving terrestrial production methods into orbit. Research published in npj Advanced Manufacturing examines how two defining features of the space environment—reduced gravity and reduced atmospheric pressure—can alter the manufacture of carbon-fiber-reinforced structures, materials widely regarded as essential for future spacecraft, habitats and large orbital infrastructure.

Carbon-fiber-reinforced polymers, commonly known as CFRPs, combine strong, lightweight carbon fibers with a polymer resin that binds the fibers into a rigid composite. Their exceptional strength-to-weight ratio makes them attractive for launch vehicles and spacecraft, where every kilogram matters. Yet manufacturing these materials is a delicate process. Fibers must be positioned accurately, resin must penetrate the reinforcement evenly, and gases or trapped voids must be removed before the material cures. On Earth, gravity and atmospheric pressure quietly assist—or complicate—each of these steps.

In space, those familiar forces change dramatically. Reduced gravity can alter how liquid resin flows through a carbon-fiber structure, while low pressure can encourage dissolved gases and volatile compounds to expand or escape. Together, these effects may influence impregnation, consolidation, curing and the final mechanical performance of a composite part. The new work by R. Strecker, T. Rieger, A. Tabelander and colleagues focuses on understanding these interactions before manufacturers attempt to produce increasingly complex structures in orbit.

The central issue is void formation. A composite that appears solid can contain microscopic pockets of air or vapor between its fibers. These voids interrupt the transfer of stress through the material and can reduce strength, stiffness and fatigue resistance. During conventional manufacturing on Earth, pressure is often applied to compress the layers and drive out unwanted gases while resin fills the spaces between fibers. In a reduced-gravity environment, however, buoyancy-driven movement is weakened, and the pathways through which bubbles travel may change. A bubble that would rise and escape during terrestrial processing could remain trapped inside the structure.

Pressure reduction introduces another layer of complexity. Lower ambient pressure can help remove volatile substances and trapped gases, but it can also cause dissolved gases in the resin to expand. If the resin is not sufficiently mobile, expanding bubbles may become locked in place as the material cures. The balance between degassing and bubble growth therefore becomes a critical manufacturing parameter. The study’s importance lies in treating pressure and gravity not as isolated variables, but as environmental conditions that can interact throughout the production cycle.

Resin flow is equally important. Carbon-fiber reinforcements are made from tightly packed filaments, creating narrow channels through which resin must travel. On Earth, gravity can influence resin distribution, especially in vertically oriented or large components. In reduced gravity, capillary forces and surface tension become relatively more significant. These forces can help draw resin into small spaces, but they may also create uneven wetting patterns depending on the fiber architecture, resin viscosity and processing orientation. Such changes could affect whether a component cures uniformly from its surface to its interior.

The findings carry implications far beyond laboratory samples. Future space manufacturers may seek to fabricate beams, pressure-vessel elements, antenna supports, solar-array components and repair patches directly in orbit. Producing these parts where they are needed could reduce the need to launch bulky finished structures from Earth. It could also enable designs too large to fit inside a rocket fairing, including trusses and habitation modules assembled gradually in space. But the economic and engineering promise of this approach depends on reliable quality control. A component that looks flawless may still fail if its internal fiber alignment, resin distribution or void content is inconsistent.

The research also highlights why manufacturing hardware designed for Earth cannot automatically be considered space-ready. Pumps, heaters, vacuum systems, molds and curing chambers must all operate under conditions in which heat transfer, fluid movement and gas removal behave differently. Temperature control is particularly important because resin viscosity changes strongly with temperature. A resin that flows readily during terrestrial processing might move more slowly or unevenly in orbit, while excessive heating could accelerate curing before impregnation is complete. Space-based production systems will therefore need carefully coordinated control of pressure, temperature, resin chemistry and processing time.

For engineers, the study provides a foundation for developing manufacturing protocols tailored to reduced-gravity environments. Instead of copying Earth-based workflows, future systems may need staged pressure changes, specialized fiber preforms, modified resin formulations or active bubble-management techniques. Sensors could monitor pressure, temperature and resin flow in real time, allowing automated systems to detect defects before a part is finished. Non-destructive inspection, including imaging and ultrasonic testing, will also be essential for verifying the integrity of components that cannot easily be returned to Earth for analysis.

The broader message is that space manufacturing is not merely an extension of industrial production—it is a new manufacturing regime governed by different physics. Understanding how gravity and pressure reshape the behavior of fluids, gases and composite materials could determine whether orbital fabrication remains a promising experiment or becomes a practical industrial capability. By examining the production of carbon-fiber-reinforced structures under space-relevant conditions, Strecker, Rieger, Tabelander and their colleagues are helping identify the hidden variables that will decide how safely and efficiently humanity can build beyond Earth.

Subject of Research: Effects of reduced gravity and reduced atmospheric pressure on the in-space manufacturing of carbon-fiber-reinforced structures

Article Title: Effects of reduced gravity and reduced atmospheric pressure on in-space manufacturing of carbon-fiber-reinforced structures

Article References: Strecker, R., Rieger, T., Tabelander, A. et al. Effects of reduced gravity and reduced atmospheric pressure on in-space manufacturing of carbon-fiber-reinforced structures. npj Adv. Manuf. 3, 26 (2026). https://doi.org/10.1038/s44334-026-00104-w

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s44334-026-00104-w

Keywords: in-space manufacturing, carbon-fiber-reinforced polymers, reduced gravity, reduced atmospheric pressure, composite materials, resin flow, void formation, space technology

Cancer researchers have reported a new strategy that combines bacterial tumor targeting, nutrient deprivation and immune stimulation in a single therapeutic design. The approach uses an engineered conjugate built from L-asparaginase and flagellin, linked to a system that directs the treatment toward calreticulin-bearing cancer cells. In experiments involving Salmonella-mediated tumor therapy, the conjugate enhanced antitumor activity compared with bacterial treatment alone, according to a study published in Cell Death Discovery.

The work addresses a long-standing challenge in cancer therapy: how to make powerful treatments concentrate inside tumors while limiting damage to healthy tissues. Attenuated strains of Salmonella have attracted interest because they can preferentially accumulate in the abnormal environment of solid tumors. Tumors often contain regions with poor oxygen levels, disorganized blood vessels and local immune suppression, conditions that can support bacterial growth. Once inside these sites, therapeutic Salmonella can act as a biological delivery platform and stimulate immune responses against malignant cells.

The researchers focused on calreticulin, a protein normally found inside the endoplasmic reticulum, where it helps regulate calcium storage and protein folding. Under cellular stress, including stress caused by chemotherapy, radiation or other anticancer treatments, calreticulin can move to the outer surface of a cancer cell. There, it functions as an “eat-me” signal, alerting immune cells that the damaged cell should be engulfed. Because surface-exposed calreticulin is associated with immunogenic forms of cell death, it provides a potential molecular address for directing therapeutic agents toward stressed tumor cells.

The experimental construct combines this targeting concept with L-asparaginase, an enzyme already used in clinical oncology, especially in the treatment of acute lymphoblastic leukemia. L-asparaginase breaks down circulating L-asparagine into aspartic acid and ammonia. Some cancer cells, particularly those with limited capacity to synthesize their own asparagine, depend heavily on the amino acid supplied through the bloodstream. Depleting extracellular asparagine can therefore interrupt protein production, trigger metabolic stress and promote cancer-cell death. The enzyme’s effectiveness, however, can be limited by immune reactions, pharmacological instability and toxicity, making targeted delivery an important goal.

The second component, flagellin, is the structural protein that forms the filament of bacterial flagella. It is also a potent molecular signal for the innate immune system. Immune cells recognize flagellin primarily through Toll-like receptor 5, while intracellular sensing pathways can activate inflammasome components such as NLRC4. These signals can promote the release of inflammatory mediators, stimulate antigen-presenting cells and help convert an immunologically “cold” tumor into one more visible to the immune system. By incorporating flagellin into the therapeutic design, the researchers sought to make the treatment not only directly toxic to tumor cells but also capable of amplifying antitumor immunity.

The study’s central finding was that the calreticulin-targeting L-asparaginase–flagellin conjugate strengthened the antitumor effects of Salmonella-based therapy. Rather than relying on a single mechanism, the treatment brings together several forms of pressure on the tumor. Salmonella can concentrate within the tumor microenvironment, the targeting component can help associate the conjugate with calreticulin-exposing cancer cells, L-asparaginase can deprive vulnerable cells of an essential nutrient, and flagellin can activate immune surveillance. The resulting combination is designed to produce a chain reaction in which metabolic stress and immune stimulation reinforce one another.

This type of combination may be particularly valuable because tumors frequently adapt when exposed to one therapeutic pressure. A cancer cell that survives nutrient deprivation may still be eliminated if immune recognition is intensified. Likewise, an immune response that is too weak to control a tumor may become more effective when bacterial localization and enzyme-mediated damage increase the number of abnormal antigens and danger signals released by dying cells. The researchers’ findings suggest that coordinating these mechanisms can improve the performance of bacteria-assisted cancer treatment in experimental settings.

The approach also reflects a broader shift in cancer research toward programmable biological medicines. Instead of treating bacteria only as infectious threats, scientists are redesigning them as localized delivery vehicles capable of carrying enzymes, immune activators or molecular probes. The advantage is spatial: a therapeutic payload can be produced or concentrated near the tumor rather than distributed uniformly throughout the body. The challenge is equally significant. Any clinical version would need precise control over bacterial attenuation, immune activation, enzyme exposure and potential inflammation, while also demonstrating reliable performance across genetically diverse tumors.

Calreticulin targeting may provide a useful way to address some of that complexity because the protein’s appearance on the cell surface is linked to cellular stress and treatment response. However, the extent and duration of calreticulin exposure can vary between tumor types and individual patients. Future studies will need to determine which cancers are most suitable for this strategy, how calreticulin levels predict treatment response and whether the conjugate can be combined safely with established immunotherapies such as immune-checkpoint inhibitors. Researchers will also need to assess pharmacology, manufacturing consistency and the possibility of immune reactions against the bacterial or enzymatic components.

The findings position the engineered conjugate as a promising experimental platform rather than an immediately available therapy. By merging tumor-homing bacteria with a calreticulin-directed enzyme and an innate immune stimulant, the study illustrates how cancer treatments can be designed to attack malignant cells on multiple biological fronts. If the results are confirmed in further preclinical testing and eventually in carefully controlled clinical trials, this strategy could help turn Salmonella from a passive carrier into an active, multifunctional partner in cancer immunotherapy.

Subject of Research: Calreticulin-targeted L-asparaginase–flagellin conjugate used with Salmonella-mediated cancer therapy.

Article Title: Calreticulin-targeting L-asparaginase-flagellin conjugate enhances Salmonella-mediated antitumor efficacy.

Article References: Nguyen, DH., Afzal, A.R., Nguyen, P.TM. et al. Calreticulin-targeting L-asparaginase-flagellin conjugate enhances Salmonella-mediated antitumor efficacy. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03300-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03300-x

Keywords: cancer immunotherapy, Salmonella, calreticulin, L-asparaginase, flagellin, tumor targeting, bacterial therapy, antitumor efficacy, immunogenic cell death

A quiet shift in silicon manufacturing could be taking shape inside a new study on porous reaction-bonded silicon nitride, a ceramic material valued for its strength, thermal stability and resistance to chemical attack. Researchers T.G. Aguirre, E. Cakmak, M.D. Richardson and colleagues are investigating how the size of additively manufactured silicon components affects their conversion into silicon nitride through a pressureless nitriding process. Published in npj Advanced Manufacturing, the work connects binder jet 3D printing with a manufacturing route that could make complex ceramic structures easier to produce.

The central idea is deceptively simple: print a component from silicon powder, then expose it to nitrogen so that the silicon reacts and forms silicon nitride. In practice, however, the transformation is governed by a network of interacting physical and chemical processes. Nitrogen must penetrate the part, reach reactive silicon surfaces and diffuse through newly formed ceramic layers. Heat must also move through the structure, while gases generated or trapped during processing must escape. As component dimensions change, these processes can behave very differently.

Binder jet additive manufacturing offers a distinctive route for creating such parts. Instead of melting powder with a laser or electron beam, the process selectively deposits a liquid binder to join powder particles layer by layer. The resulting “green” component is then typically dried and thermally treated to remove the binder, leaving a fragile, porous body. For silicon-based structures, that interconnected porosity can become a processing advantage, allowing nitrogen to travel through the material during the subsequent reaction.

The researchers’ focus on size effects addresses a major challenge in scaling ceramic additive manufacturing from laboratory specimens to useful components. A thin printed sample may nitridize relatively quickly because nitrogen has only a short distance to travel. A thicker or larger part presents a far more demanding environment. Its interior can receive nitrogen more slowly, and the reaction front may progress unevenly from the outer surface inward. Differences in heating rate, temperature distribution and gas transport can produce variations in conversion, density and final microstructure.

The term “pressureless nitriding” is crucial to the study’s technological appeal. Many advanced ceramic manufacturing methods depend on external pressure, specialized furnaces or high-energy consolidation steps to achieve the desired structure. A pressureless route instead relies on controlled heating and the chemical affinity between silicon and nitrogen. If the reaction can be managed uniformly, manufacturers could potentially create intricate silicon nitride components without applying mechanical pressure during conversion, simplifying equipment requirements and expanding the range of printable geometries.

Silicon nitride is an especially attractive target because it combines several properties that are difficult to obtain in a single engineering material. It can withstand high temperatures, resist wear and corrosion, and maintain useful mechanical performance under demanding conditions. Those characteristics have made silicon nitride relevant to applications ranging from bearings and cutting tools to heat-resistant components and advanced energy systems. A porous version offers additional possibilities, including lightweight structures, filtration, thermal management and engineered surfaces where controlled pathways through the material are valuable.

The study’s attention to porosity is equally important. In reaction-bonded ceramics, pores are not merely defects; they can serve as channels for reactant transport. At the same time, excessive or poorly distributed porosity can weaken the final component and interfere with complete conversion. The scientific challenge is therefore to balance openness and strength. The printed silicon body must remain permeable enough for nitrogen to reach its interior, while the reaction must generate a coherent silicon nitride framework rather than leaving unreacted silicon or creating damaging gradients.

By examining components of different sizes, the researchers are addressing a question with direct implications for industrial design: can processing rules developed for small printed samples be applied to larger parts? The answer depends on how reaction kinetics, diffusion and heat transfer scale with geometry. A process that appears reliable in a small coupon may produce a different result in a thick wall, enclosed channel or complex lattice. Understanding those differences can help engineers determine allowable dimensions, optimize furnace schedules and design structures around the chemistry of nitridation rather than treating manufacturing as a purely geometric exercise.

The broader significance of the work lies in the convergence of three fields: powder-based additive manufacturing, reaction-bonded ceramics and transport-driven materials processing. Instead of printing a finished ceramic directly, the approach uses additive manufacturing to create a carefully engineered precursor and then transforms it chemically. That strategy could unlock shapes that are difficult to machine from dense silicon nitride, while reducing the need for conventional molds and tooling. As manufacturers seek lighter, more complex and more resource-efficient components, controlling size-dependent reactions may become as important as improving printer resolution.

The research arrives at a moment when additive manufacturing is moving beyond demonstrations of intricate shapes toward repeatable production of functional materials. Its emphasis on pressureless nitriding of binder jet additively manufactured silicon highlights a practical bottleneck often hidden behind spectacular 3D-printing images: the printed object is only the beginning. The final performance depends on what happens during post-processing, when gases, heat and chemical reactions determine the internal structure. By clarifying how component size influences that transformation, Aguirre, Cakmak, Richardson and their collaborators are helping map a route from powder and binder to porous silicon nitride parts designed for the high-temperature technologies of the future.

Subject of Research: Porous reaction-bonded silicon nitride produced through pressureless nitriding of binder jet additively manufactured silicon, with a focus on size effects.

Article Title: Porous reaction-bonded silicon nitride: Size effects for pressureless nitriding of binder jet additively manufactured silicon

Article References: Aguirre, T.G., Cakmak, E., Richardson, M.D. et al. “Porous reaction-bonded silicon nitride: Size effects for pressureless nitriding of binder jet additively manufactured silicon.” npj Advanced Manufacturing (2026). https://doi.org/10.1038/s44334-026-00110-y

Image Credits: AI Generated

DOI: 10.1038/s44334-026-00110-y

Keywords: Silicon nitride, reaction-bonded ceramics, pressureless nitriding, binder jet additive manufacturing, silicon, porous materials, size effects.

A short-term decision to eat fewer or no animal products may begin reshaping the human body at the molecular level far sooner than many people expect, according to a new study published in Nature Communications. Research by A. Simistiras, O. Bocher, C. Emmanouil and colleagues examined how restricting animal-derived foods affects both gene activity and protein production in humans, revealing a complex biological response that unfolds beneath the visible changes on a plate.

The study focuses on proteogenomics, an approach that combines two powerful layers of biological information. Genomics and transcriptomics examine the instructions encoded in DNA and the messenger RNA molecules produced when genes are activated. Proteomics, by contrast, measures the proteins that cells actually manufacture. Because proteins perform most of the body’s day-to-day work—from transporting nutrients to controlling immune reactions—studying them alongside gene activity can provide a more direct picture of how physiology responds to dietary change.

Rather than treating diet as a distant influence on long-term health, the research highlights it as an immediate biological signal. When people reduce their intake of animal products, the body is exposed to a different mixture of amino acids, fats, vitamins, minerals and other bioactive compounds. The quantity and timing of these nutrients can alter metabolic pathways, cellular signaling and the activity of genes involved in maintaining tissues. The researchers’ proteogenomic analysis was designed to capture these interconnected effects during a relatively short dietary intervention.

The significance of the work lies in its ability to distinguish between what cells are instructed to do and what they ultimately do. A gene may become more active without producing a corresponding increase in its protein, while a protein may remain stable because of slower turnover or regulation after translation. By examining both molecular layers, the study offers a more refined view of diet-responsive biology than either gene-expression or protein measurements alone. This is particularly important for nutrition research, where modest changes in multiple pathways can combine to influence health.

The findings indicate that restricting animal products can produce measurable molecular shifts even over a limited period. These changes do not represent a simple biological switch from “animal-based” to “plant-based” physiology. Instead, they appear as a network of coordinated responses involving nutrient processing, energy metabolism and cellular regulation. Some proteins may respond directly to altered nutrient availability, while others may change indirectly as tissues adapt to new metabolic demands. The result is a biological signature of dietary transition rather than a single marker that explains every effect.

Such signatures could eventually help researchers understand why individuals respond differently to the same eating pattern. Two people can consume similar diets yet experience distinct changes in blood chemistry, metabolism or immune activity because of differences in genetics, gut microorganisms, age, lifestyle and baseline health. Proteogenomic profiles may help identify these sources of variation by showing which pathways are activated in each person. In the future, that information could support more individualized nutritional guidance instead of assuming that one dietary pattern produces the same outcome for everyone.

The study also underscores an important distinction between molecular response and clinical benefit. Detecting changes in proteins or gene activity does not automatically prove that a diet will prevent disease, improve performance or extend lifespan. Molecular alterations can be adaptive, neutral or potentially harmful depending on their intensity, duration and biological context. The research therefore provides evidence that the body responds rapidly to dietary restriction, while longer and larger studies will be needed to determine how these responses relate to cardiovascular health, metabolic disease, immune function and other outcomes.

The work arrives as plant-forward diets are drawing increasing interest for environmental, ethical and health reasons. Yet public discussions often reduce the science to competing claims about whether animal products are categorically beneficial or harmful. The proteogenomic perspective offers a more nuanced alternative. It suggests that dietary effects emerge through dozens, perhaps hundreds, of interacting pathways, and that the consequences of removing or reducing a food category depend on what replaces it. A diet rich in minimally processed legumes, grains, nuts, seeds, fruits and vegetables may produce a very different molecular response from one dominated by refined plant-based products.

For scientists, the study demonstrates the value of observing dietary change across multiple biological scales. For the public, its message is both striking and practical: the body does not wait years to notice what people eat. Even short-term restriction of animal products can be reflected in the molecular machinery of human cells. The findings do not settle the broader debate over the ideal diet, but they add a new layer of evidence showing that food choices are rapidly translated into biological signals—and that understanding those signals may be key to designing healthier, more personalized nutrition strategies.

Subject of Research: The proteogenomic effects of short-term restriction of animal products in humans.

Article Title: Diet-responsive proteogenomic effects following short-term restriction of animal products in humans.

Article References: Simistiras, A., Bocher, O., Emmanouil, C. et al. Diet-responsive proteogenomic effects following short-term restriction of animal products in humans. Nature Communications (2026). https://doi.org/10.1038/s41467-026-76379-6

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76379-6

Keywords: proteogenomics, nutrition, animal-product restriction, plant-based diet, gene expression, protein response, human metabolism, dietary intervention, precision nutrition

Fuchs endothelial corneal dystrophy, a progressive disorder that can gradually cloud the cornea and impair vision, may be driven by a cellular process more complex than simple cell loss. A new study published in Cell Death Discovery reports that ultraviolet-A light can induce chronic hyperploidization in corneal endothelial cells, triggering changes associated with fibrosis. The findings connect long-term genome abnormalities in post-mitotic cells to the structural deterioration observed in this increasingly recognized eye disease.

The cornea depends on a thin inner layer of endothelial cells to maintain its transparency. These cells regulate the movement of fluid between the cornea and the anterior chamber of the eye, preventing the tissue from becoming waterlogged. Unlike many cell types, human corneal endothelial cells have limited ability to divide and replenish themselves. When they are damaged or lost, neighboring cells may enlarge and stretch to cover the affected area, but this compensation has limits. In Fuchs endothelial corneal dystrophy, the endothelial layer progressively becomes dysfunctional, allowing fluid accumulation and producing corneal swelling, haze and visual distortion.

The study focuses on hyperploidization, a condition in which cells acquire extra sets or copies of chromosomes. In a healthy cell cycle, DNA is replicated and then evenly distributed when a cell divides. Post-mitotic cells, however, are not expected to continue cycling through repeated rounds of DNA replication. If DNA replication occurs without successful cell division, the result can be a cell with an enlarged genome and multiple chromosome sets. This state, known as polyploidy or hyperploidization depending on its extent and context, can alter cell size, metabolism, gene activity and responses to stress.

The researchers investigated how ultraviolet-A, or UVA, light affects cells associated with Fuchs endothelial corneal dystrophy. UVA has a longer wavelength than ultraviolet-B and can penetrate biological tissues more deeply. Although the eye possesses protective mechanisms, persistent or excessive exposure to light-generated stress can damage cellular components, including DNA, proteins and mitochondria. The study indicates that UVA exposure does not merely cause an acute injury that cells either repair or fail to survive. Instead, it can establish a chronic hyperploid state in cells that no longer divide normally.

That distinction is important because a cell can remain alive while becoming increasingly dysfunctional. Hyperploid cells may continue to produce proteins, communicate with neighboring cells and modify their surrounding environment, even as their enlarged genomes disrupt normal regulation. In the corneal endothelium, such persistent abnormalities could interfere with the machinery responsible for maintaining fluid balance and tissue transparency. The research links this long-lasting cellular state to the activation of fibrotic processes, suggesting that damaged endothelial cells may help remodel the cornea rather than simply disappearing.

Fibrosis is the formation or accumulation of excessive connective-tissue components, particularly extracellular matrix proteins such as collagens. During wound healing, matrix production can provide temporary structural support. When the response persists, however, the tissue can stiffen, become disorganized and lose its normal optical properties. In the context of Fuchs endothelial corneal dystrophy, fibrosis may contribute to the loss of corneal clarity and the progression of visual impairment. The study’s central message is that chronic hyperploidization may act as an upstream signal that pushes post-mitotic cells toward this pathological remodeling.

The findings also help explain why a disease affecting a specialized, non-dividing cell population can progress over time. A conventional view of cellular damage often emphasizes apoptosis, necrosis or the gradual depletion of functional cells. The new work highlights another possibility: injured cells may survive in a permanently altered condition and actively influence disease progression. By retaining metabolic activity while carrying abnormal quantities of DNA, these cells could produce signals that encourage inflammation, matrix deposition or changes in the behavior of nearby cells.

The UVA connection raises questions about how environmental stress interacts with inherited susceptibility. Fuchs endothelial corneal dystrophy has genetic and age-related components, and the disease does not arise from a single universal cause. The study does not establish that UVA exposure alone causes the disorder, but it provides a mechanism through which light-associated stress could worsen cellular instability in vulnerable corneal tissue. This may help researchers examine whether cumulative exposure, cellular antioxidant capacity and pre-existing genetic changes combine to determine how rapidly the disease advances.

From a treatment perspective, the work points toward targets beyond replacing lost endothelial cells. Future strategies might seek to prevent abnormal DNA replication, stabilize genome integrity, suppress the fibrotic signals released by hyperploid cells or protect the corneal endothelium from chronic light-induced stress. Such approaches would require careful testing, because polyploidy can serve useful roles in some normal tissues, and broadly blocking cell-cycle or repair pathways could produce harmful effects. The challenge will be to distinguish pathological hyperploidization from adaptive genome changes that help cells survive.

The study ultimately presents Fuchs endothelial corneal dystrophy as a disease of cellular identity as well as cellular survival. UVA-induced chronic hyperploidization appears to place post-mitotic corneal endothelial cells in a persistent state of genomic imbalance, where they can contribute to fibrosis and tissue failure. By connecting light stress, abnormal DNA content and corneal scarring, the research offers a new framework for understanding why the disease can continue even after the initial injury has passed—and provides a potential roadmap for therapies designed to interrupt the process before vision is permanently compromised.

Subject of Research: Ultraviolet-A light-induced chronic hyperploidization and fibrosis in post-mitotic corneal endothelial cells affected by Fuchs endothelial corneal dystrophy

Article Title: Ultraviolet-A light-induced chronic hyperploidization causes fibrosis in post-mitotic cells affected by Fuchs endothelial corneal dystrophy

Article References: Adhikari, Y., Parekh, M., Deshpande, N. et al. Ultraviolet-A light-induced chronic hyperploidization causes fibrosis in post-mitotic cells affected by Fuchs endothelial corneal dystrophy. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03292-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-03292-8

Keywords: Fuchs endothelial corneal dystrophy, ultraviolet-A, UVA, hyperploidization, polyploidy, corneal endothelial cells, fibrosis, post-mitotic cells, genome instability, corneal disease

Lung adenocarcinoma is one of the most common forms of lung cancer and remains a major cause of cancer-related death worldwide. Although advances in imaging, molecular testing and targeted treatment have transformed care for some patients, the disease can behave very differently from one person to another. A new study published in the British Journal of Cancer is examining whether a protein called PDLIM2 could help explain that difference—and potentially become both a prognostic biomarker and a target for future therapies.

The research, led by Ashouri, Sun, Krause and colleagues, focuses on the biological and clinical significance of PDLIM2 in lung adenocarcinoma. A prognostic biomarker is a measurable feature that helps indicate how a disease may progress, including the likelihood of recurrence, treatment resistance or reduced survival. A therapeutic target, by contrast, is a molecule or pathway that can be manipulated with a drug or other intervention. The possibility that one protein could serve both roles makes PDLIM2 particularly interesting to cancer researchers.

PDLIM2 belongs to a family of proteins containing LIM domains, compact structural modules that help organize interactions between proteins. These proteins can act as molecular adaptors, bringing signaling components into the same cellular neighborhoods and influencing how cells respond to external stimuli. PDLIM2 has also been linked to the regulation of transcription factors, including nuclear factor kappa B, or NF-κB, a signaling regulator involved in inflammation, immune responses, cell survival and cancer biology. Because these processes are frequently altered in tumors, changes in PDLIM2 activity could have consequences extending far beyond a single cellular pathway.

Lung adenocarcinoma develops through the accumulation of genetic, epigenetic and environmental changes that allow abnormal cells to grow, invade surrounding tissue and spread to distant organs. Tumor cells also interact continuously with immune cells, connective tissue and blood vessels in their surrounding microenvironment. A protein such as PDLIM2 could influence cancer progression directly inside tumor cells or indirectly by altering inflammatory communication between the tumor and its surroundings. Understanding which of these possibilities is most important is essential before the protein can be considered a reliable clinical marker.

The investigators’ work explores whether PDLIM2 levels or activity are associated with meaningful features of lung adenocarcinoma. Such analyses typically compare molecular patterns in tumor and normal tissue, relate gene or protein expression to clinical outcomes, and examine whether a biomarker adds information beyond established factors such as tumor stage, histological characteristics and patient treatment. If PDLIM2 consistently tracks with disease behavior, it could eventually help doctors identify patients whose tumors require closer monitoring or more intensive treatment.

However, a biomarker is not automatically useful simply because it is statistically associated with cancer. For a molecule to become clinically valuable, researchers must establish how accurately and reproducibly it predicts outcomes, whether the result applies across different patient groups, and whether testing can be performed using practical samples and standardized methods. The distinction between correlation and causation is equally important. A high or low level of PDLIM2 may reflect an underlying cancer process without being responsible for it. The study’s therapeutic implications therefore depend on experimental evidence showing whether changing PDLIM2 can alter tumor-cell behavior.

The therapeutic-target question is especially challenging in lung adenocarcinoma, a disease that often contains several cancer-driving alterations at once. Targeted drugs against molecules such as EGFR, ALK, ROS1 and KRAS have produced significant benefits for selected patients, but resistance commonly emerges. Tumors can bypass blocked pathways, acquire new mutations or recruit protective signals from their microenvironment. If PDLIM2 participates in a separate or complementary network, targeting it could theoretically provide another way to disrupt tumor survival or progression. That possibility remains a research hypothesis requiring validation rather than an established treatment strategy.

Laboratory studies will be crucial for determining how PDLIM2 functions in different cellular contexts. Researchers may need to silence or increase the protein in lung adenocarcinoma models, monitor effects on proliferation, migration, invasion and cell death, and test whether PDLIM2 changes the response to existing therapies. Studies using animal models and patient-derived tumor systems could further reveal whether manipulating the protein affects tumor growth in a complex biological environment. At the same time, clinical datasets will be needed to establish whether PDLIM2 has independent prognostic value and whether it can support treatment decisions.

The appeal of the new research lies in its attempt to connect molecular biology with patient outcomes. Modern oncology increasingly depends on biomarkers that do more than describe a tumor; the most useful markers help predict what will happen and guide what should be done next. PDLIM2 could become part of that effort if future studies confirm its role across diverse populations and demonstrate that it can be measured reliably. For now, the work adds to a growing investigation into the signaling architecture of lung adenocarcinoma, where proteins once considered secondary components may hold clues to why some tumors remain controllable while others become aggressive and treatment-resistant.

Subject of Research: PDLIM2 as a prognostic biomarker and potential therapeutic target in lung adenocarcinoma.

Article Title: Exploring PDLIM2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma.

Article References: Ashouri, K., Sun, F., Krause, H. et al. Exploring PDLIM2 as a prognostic biomarker and therapeutic target in lung adenocarcinoma. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03570-3

Image Credits: AI Generated

DOI: 10.1038/s41416-026-03570-3

Keywords: PDLIM2, lung adenocarcinoma, lung cancer, prognostic biomarker, therapeutic target, cancer signaling, precision oncology, NF-κB, molecular oncology

The apparent benefits of updated COVID-19 vaccines in older adults may be influenced by more than the vaccines themselves, according to a study examining the “healthy vaccinee effect,” a form of bias that can complicate observational research. Published in Nature Communications, the work by Lyth, Spreco, Hinkula and colleagues focuses on how differences between people who receive vaccination and those who do not can alter estimates of vaccine effectiveness, particularly in elderly populations whose health status can change rapidly.

Updated COVID-19 vaccines are designed to improve protection against circulating SARS-CoV-2 variants, especially protection against severe disease, hospitalization and death. Because randomized clinical trials are not usually repeated for every reformulated vaccine and every emerging variant, researchers frequently rely on real-world health data. These studies compare outcomes among vaccinated and unvaccinated people, but the two groups may differ in important ways before vaccination occurs. Such differences can produce an apparent vaccine benefit—or obscure a real one—even when the analysis carefully accounts for age and medical conditions.

The healthy vaccinee effect arises when people who are vaccinated are temporarily healthier, more active or better connected to healthcare services than those who remain unvaccinated. Individuals may postpone vaccination during an acute illness, after hospitalization or when they are approaching the end of life. At the same time, people who attend vaccination appointments may be more likely to receive preventive care, follow medical advice and seek treatment early. These characteristics are not necessarily caused by vaccination, but they can lower the vaccinated group’s risk of death or hospitalization during the period used for analysis.

This issue is particularly important in older populations. Elderly people often have multiple chronic conditions, fluctuating functional status and frequent contact with hospitals or long-term care facilities. A person may be eligible for a vaccine campaign but unable to receive the dose because of an acute health problem. If that person later dies or is hospitalized, conventional analyses may attribute the worse outcome to the absence of vaccination, even though the underlying illness was already present. Conversely, if researchers compare groups immediately after vaccination without accounting for this selection process, the vaccine may appear more protective than it truly is.

The study evaluates how this bias affects assessments of updated COVID-19 vaccines in elderly populations. Its central scientific contribution is to treat vaccination not simply as an exposure, but as an event embedded in a changing health trajectory. The health of older adults is not static: frailty, infection, recent hospitalization and access to care can all influence whether and when vaccination occurs. By examining these time-dependent factors, the researchers draw attention to the difference between a vaccine’s biological effect and the characteristics of the people who are able to receive it at a particular moment.

In epidemiological terms, the healthy vaccinee effect is a form of confounding and selection bias. Confounding occurs when another factor is associated with both vaccination and the outcome being measured. Selection bias occurs when inclusion in the vaccinated or comparison group depends on health-related circumstances. Timing can intensify both problems. If follow-up begins on the day of vaccination for one group but at an arbitrary date for another, the groups may not have equivalent baseline risks. Researchers therefore need to define an appropriate index date, align observation periods and account for recent illness, healthcare use and changes in eligibility.

The challenge is not merely statistical. A vaccine can provide strong protection against severe COVID-19 while producing a smaller or more variable effect against infection, depending on the variant, time since vaccination, prior immunity and the outcome being studied. If an observational analysis reports a lower mortality rate among vaccinated people, that result may reflect a combination of direct vaccine protection and the healthier profile of vaccine recipients. Separating these components requires careful design, including adjustment for measured risk factors and, where possible, comparison strategies that mimic a randomized trial.

The findings have practical implications for interpreting public-health evidence. Estimates of updated vaccine effectiveness should not be read in isolation from the population being studied, the timing of vaccination and the definition of the unvaccinated comparison group. Researchers may need to conduct sensitivity analyses, use negative-control outcomes, examine short intervals after vaccination and account for healthcare-seeking behavior. Analyses that compare people with similar recent health histories, or that use methods designed for time-varying confounding, can help determine whether an observed association is likely to represent a genuine vaccine effect.

The study does not undermine the value of COVID-19 vaccination for older adults; rather, it highlights the methodological care required to measure that value accurately. For clinicians, policymakers and the public, the message is that real-world vaccine evidence is strongest when biological protection is evaluated alongside the circumstances that determine who gets vaccinated and when. As SARS-CoV-2 continues to evolve and vaccine formulations are periodically updated, understanding the healthy vaccinee effect will remain essential for distinguishing the protection delivered by immunization from the protection that appears because healthier people are more likely to receive it.

Subject of Research: Healthy vaccinee effect and the evaluation of updated COVID-19 vaccines in elderly populations.

Article Title: Healthy vaccinee effect in the evaluation of updated COVID-19 vaccines in elderly populations.

Article References:

Lyth, J., Spreco, A., Hinkula, J. et al. Healthy vaccinee effect in the evaluation of updated COVID-19 vaccines in elderly populations. Nat Commun 17, 8014 (2026). https://doi.org/10.1038/s41467-026-76312-x

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41467-026-76312-x

Keywords: COVID-19 vaccines, updated vaccines, SARS-CoV-2, elderly populations, healthy vaccinee effect, vaccine effectiveness, epidemiology, observational studies, confounding, public health.

Ebola vaccine research has taken a step toward broader protection against one of the most persistent challenges in filovirus medicine: the existence of multiple Ebola virus species that can cause severe human disease. In a study published in Nature Communications, Weidle, Brunette, Wrenn and colleagues report that a pan-Ebolavirus nanoparticle vaccine protected rodents from lethal infection with both Zaire ebolavirus and Sudan ebolavirus. The finding is significant because vaccines designed around a single viral species may not provide reliable protection against genetically distinct Ebola viruses, particularly those responsible for separate outbreaks in different regions of Africa.

Ebola viruses belong to the filovirus family, a group of filament-shaped, enveloped viruses capable of causing hemorrhagic fever. Zaire ebolavirus is the species most closely associated with the large West African epidemic of 2014–2016 and remains the primary target of licensed Ebola vaccines. Sudan ebolavirus, however, is sufficiently different at the molecular level to present a separate immunological challenge. Outbreaks caused by Sudan virus have repeatedly demonstrated the need for countermeasures that are not limited to one viral lineage. A vaccine capable of recognizing shared features across several Ebola viruses could therefore simplify outbreak preparedness and improve the speed of emergency responses.

The strategy described in the study is based on nanoparticle vaccine technology. Nanoparticles can be engineered to present viral antigens in a highly organized, repetitive arrangement that resembles the dense surface of an actual virus. This geometry can improve the activation of B cells, the immune cells responsible for producing antibodies, by efficiently cross-linking B-cell receptors. Nanoparticles may also enhance the delivery of antigens to lymphoid tissues, where immune responses are initiated and refined. Rather than presenting a soluble protein in a relatively dispersed form, the platform is designed to display Ebola-related molecular targets in a configuration that can stimulate a stronger and more coordinated response.

A central challenge in creating a pan-Ebolavirus vaccine is selecting antigens that are both accessible to the immune system and sufficiently conserved among viral species. Ebola viruses share a broad structural organization, but their surface glycoproteins contain regions that vary in sequence and shape. The glycoprotein is especially important because it enables the virus to attach to host cells and enter them. Antibodies that bind to vulnerable regions of this protein can block infection, interfere with membrane fusion or mark viral particles for destruction by immune cells. A broadly protective vaccine must therefore encourage immunity against sites that remain functionally important even as the virus evolves.

In the rodent experiments, the vaccine was evaluated against lethal challenge with viruses representing the Zaire and Sudan species. Such challenge studies are designed to test whether vaccination-induced immunity can prevent severe disease after exposure to a high-risk pathogen. Protection in this setting reflects the combined activity of several immune mechanisms, including neutralizing antibodies, antibody-dependent cellular functions and virus-specific T-cell responses. Antibodies can prevent viral entry into cells, while T cells and other immune components help eliminate infected cells and limit the spread of infection. The reported protection across both virus species indicates that the nanoparticle formulation generated immune recognition broad enough to cross an important species barrier.

The result does not mean that the viruses are identical, nor does it establish that the vaccine will perform in humans in the same way. Rodent immune systems, dosing schedules and routes of exposure can differ substantially from human conditions. Animal challenge models are nevertheless a crucial stage in vaccine development because they reveal whether an immune response is capable of controlling infection under stringent circumstances. They also allow researchers to examine how quickly protection develops, how long it persists and whether vaccination reduces viral replication and tissue damage. Further studies will be needed to determine which immune markers best predict protection and whether the platform can be adapted for use against additional Ebola species.

The broad scope of the vaccine could have practical implications for epidemic preparedness. Existing Ebola vaccination strategies have demonstrated that immunization can protect against severe disease, but the need to match a vaccine to a particular viral species can complicate decisions during an outbreak. When the causative virus is initially unknown, health authorities may face uncertainty over which product to deploy. A pan-Ebolavirus formulation could potentially reduce that uncertainty by providing coverage against more than one major pathogen. It could also be useful for laboratory personnel, health-care workers and communities living in regions where different Ebola species may emerge over time.

Nanoparticle approaches may offer additional advantages beyond breadth. Their modular design can allow scientists to alter the antigen displayed on the particle without rebuilding the entire vaccine concept from the beginning. This flexibility is relevant to viral pathogens, which can change through mutation and may contain several related species with distinct antigenic profiles. At the same time, the platform must meet demanding standards for manufacturing consistency, stability, storage and safety. A formulation that performs well in laboratory animals must eventually demonstrate reproducible production, acceptable tolerability and durable protection in progressively more advanced models before clinical testing can be considered.

The study’s findings place nanoparticle engineering among the most promising strategies for developing next-generation filovirus vaccines. By combining multivalent antigen presentation with targets shared across Zaire and Sudan viruses, the researchers have demonstrated a route toward broader Ebola protection in rodents. The work does not eliminate the need for species-specific vaccines or replace surveillance, rapid diagnostics and infection-control measures. It does, however, provide experimental evidence that a single vaccine design can generate protective immunity against two medically important Ebola viruses. As outbreaks continue to expose gaps in preparedness, such cross-species technologies could become an important part of the scientific effort to prevent Ebola from turning a local emergence into a global health crisis.

Subject of Research: Pan-Ebolavirus nanoparticle vaccine protection against lethal Zaire and Sudan virus infection in rodents

Article Title: Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses

Article References: Weidle, C., Brunette, N., Wrenn, S.P. et al. Pan-Ebolavirus nanoparticle vaccine provides protection in rodents from lethal infection by Zaire and Sudan viruses. Nature Communications (2026). https://doi.org/10.1038/s41467-026-76114-1

Image Credits: AI Generated

DOI: 10.1038/s41467-026-76114-1

Keywords: Ebola virus, Zaire ebolavirus, Sudan ebolavirus, pan-Ebolavirus vaccine, nanoparticle vaccine, filoviruses, viral immunology, infectious disease, vaccine research, rodent models

Falls among older adults often begin with changes too subtle to be noticed during an ordinary walk. A person may still appear steady while moving through a familiar environment, yet struggle when asked to divide attention between walking and another task. A new study by researchers Dong, Hu, Guo and colleagues examines whether machine-learning techniques can identify this hidden vulnerability in community-dwelling older adults by analyzing how gait changes during dual-task walking. Published in BMC Geriatrics in 2026, the research focuses on a potentially powerful combination of digital movement measurement and artificial intelligence: spatiotemporal gait parameters recorded while people walk and perform a second mental or motor activity.

Walking is not a single, automatic action. It requires continuous coordination between the brain, muscles, sensory systems and balance mechanisms. When a person walks while counting backward, answering questions or carrying an object, the nervous system must distribute attention between locomotion and the competing task. This is known as dual-task walking. Older adults who have limited cognitive or physical reserve may respond by slowing down, shortening their steps, widening their base of support or becoming more irregular in their timing. These adaptations can provide clues about fall susceptibility that may remain invisible during conventional clinical walking tests.

The study’s central idea is that gait should be evaluated under realistic cognitive pressure rather than only in ideal, distraction-free conditions. Spatiotemporal gait parameters describe measurable features of movement across time and space, including walking speed, stride length, step time, cadence, stance duration and the variability between consecutive steps. In a dual-task setting, researchers can also examine the degree to which these variables change compared with normal walking. This difference, often called dual-task cost, can reveal how much a person’s mobility is affected when attention is divided. A larger cost may indicate reduced ability to manage competing demands while remaining stable.

Machine learning offers a way to analyze these patterns simultaneously. Traditional clinical assessment may focus on one or two measurements, such as walking speed or the number of previous falls. A machine-learning model can process many variables at once and search for combinations associated with elevated risk. Depending on the model design, the system may learn from labeled examples, in which participants’ gait data are linked to fall-related outcomes, and then estimate risk for new individuals. Algorithms can detect nonlinear relationships that are difficult to capture with conventional statistical methods, although their usefulness depends heavily on the quality, size and representativeness of the data used for training.

The community setting is especially important. Many studies of balance and falls are conducted in hospitals or specialist laboratories, where participants may be healthier, more closely supervised or less representative of the broader older population. Community-dwelling adults live independently and encounter the complex conditions that make falls more likely: distractions, uneven surfaces, hurried movement, household obstacles and the need to perform several tasks at once. By focusing on this group, the research addresses a practical question for preventive medicine: can accessible gait testing identify people who appear independent but may require additional support before a serious fall occurs?

A potential advantage of this approach is its ability to move fall-risk assessment toward objective, repeatable measurement. Gait sensors, pressure-sensitive walkways, wearable devices or camera-based systems can convert movement into numerical data. Those data may be more sensitive than a brief visual observation, particularly when they capture step-to-step variability and changes induced by a secondary task. In the future, similar measurements could potentially be collected in clinics, rehabilitation centers or even at home. However, a prediction tool would need to be tested across different ages, health conditions, walking environments and technology platforms before it could be trusted for widespread use.

The research also highlights the technical challenges behind apparently simple predictions. Falls are influenced by numerous factors, including muscle strength, vision, medication use, reaction time, fear of falling, neurological disease and environmental hazards. Gait features alone cannot explain every incident. A machine-learning model may also perform impressively on the data used to develop it but less reliably on people from another population, a problem known as limited generalizability or overfitting. For clinical adoption, researchers must therefore evaluate calibration, sensitivity and specificity, test the model on independent datasets and make its decisions understandable to health professionals and patients.

Although the citation identifies the study’s objective and methodology, it does not provide detailed numerical findings such as sample size, predictive accuracy or the specific algorithm used. Those results will determine how close this technology is to practical deployment. Even so, the study reflects a broader shift in geriatric care: fall prevention is increasingly being treated as a problem of measurable, dynamic performance rather than a simple checklist of past incidents. By combining dual-task gait analysis with machine learning, the researchers are investigating whether the body’s response to distraction can serve as an early warning signal—one that could eventually help clinicians intervene before a dangerous fall changes an older person’s independence.

Subject of Research: Fall-risk prediction in community-dwelling older adults using machine learning and dual-task spatiotemporal gait parameters.

Article Title: Machine learning-based fall risk prediction in community-dwelling older adults using dual-task spatiotemporal gait parameters.

Article References: Dong, G., Hu, H., Guo, Y. et al. “Machine learning-based fall risk prediction in community-dwelling older adults using dual-task spatiotemporal gait parameters.” BMC Geriatrics (2026). https://doi.org/10.1186/s12877-026-07998-3

Image Credits: AI Generated

DOI: 10.1186/s12877-026-07998-3

Keywords: machine learning, fall risk prediction, older adults, community-dwelling older adults, dual-task walking, gait analysis, spatiotemporal gait parameters, geriatric medicine, balance, mobility.

As populations age, scientists are looking more closely at a hidden biological process that may help explain why some older adults remain mobile and independent while others experience a rapid decline in strength, balance, and endurance. A systematic review by A. Boshnjaku, R. Obërtinca, M. Hoxha, and colleagues examines whether five inflammation-related biomarkers—CRP, high-sensitivity CRP, interleukin-6, interleukin-10, and tumor necrosis factor-alpha—are linked to physical performance in older adults living in the community. Published in BMC Geriatrics, the review focuses on a question with major implications for healthy aging: can signals circulating in the blood reveal who is at greater risk of losing physical function?

The study centers on chronic, low-grade inflammation, a biological condition often associated with aging and commonly described as “inflammaging.” Unlike the intense inflammation triggered by an infection or injury, inflammaging can persist quietly over years. It may be influenced by immune-system changes, excess body fat, physical inactivity, chronic disease, and cellular stress. Although inflammation is essential for repairing tissue and fighting pathogens, prolonged activation can affect muscle metabolism, blood-vessel function, nervous-system signaling, and energy production. These changes could, in theory, make everyday movements such as walking, rising from a chair, or climbing stairs increasingly difficult.

C-reactive protein, or CRP, is one of the most widely used indicators of systemic inflammation. It is produced primarily by the liver in response to inflammatory signals, especially interleukin-6. Standard CRP testing is useful for detecting relatively pronounced inflammatory activity, while high-sensitivity CRP, known as hs-CRP, can measure much lower concentrations. That distinction matters in research on older adults, where subtle inflammatory differences may exist even when there is no obvious acute illness. However, neither CRP nor hs-CRP identifies a single disease or proves that inflammation itself caused a decline in physical ability.

The review also considers three signaling proteins known as cytokines. Interleukin-6, or IL-6, can promote inflammation but also participates in muscle adaptation and energy regulation, making its effects highly dependent on timing, tissue, and physiological context. Tumor necrosis factor-alpha, or TNF-α, is a potent inflammatory mediator that can influence muscle protein breakdown and interfere with insulin signaling. Interleukin-10, or IL-10, generally acts as an anti-inflammatory regulator, helping restrain excessive immune activation. Examining these markers together offers a more nuanced picture than relying on a single laboratory value.

Physical performance is a crucial measure of aging because it reflects how effectively multiple systems work together. Muscle strength alone does not determine whether a person can remain independent. Walking speed, repeated chair stands, balance, grip strength, endurance, and composite tests such as the Short Physical Performance Battery can reveal the combined effects of the muscular, cardiovascular, neurological, and skeletal systems. For people living outside hospitals and care facilities, these measures may also provide a practical snapshot of resilience in everyday life. A small difference in performance can translate into a major difference in fall risk, mobility, and the ability to manage daily activities.

By bringing together evidence from studies of community-dwelling older adults, the authors address an important gap between laboratory research and real-world aging. Older people living independently are not a uniform group: some have multiple chronic conditions, while others remain highly active; some take anti-inflammatory medications, and others do not. Diet, smoking, obesity, socioeconomic conditions, sleep, recent infections, and exercise can all alter cytokine levels and physical performance. A systematic review can help determine whether associations between biomarkers and function appear consistently across this complex population or whether they vary substantially from one study to another.

The review’s importance lies not only in asking whether inflammatory markers are associated with poorer performance, but also in highlighting the limitations of interpreting such relationships. A high biomarker level may be a consequence of frailty, reduced activity, obesity, or an undiagnosed illness rather than the original cause of decline. Conversely, a single blood sample may fail to capture fluctuations in inflammation over time. Differences in laboratory methods, cutoff values, participant health, medication use, and performance tests can make studies difficult to compare. These issues are central when translating population-level associations into decisions about an individual patient.

The findings may ultimately support a broader approach to healthy aging in which inflammation is considered alongside strength, nutrition, cardiovascular health, cognition, and social environment. The biomarkers discussed in the review are not presented as standalone tests that can predict the future with certainty. Instead, they may help researchers understand why physical function changes and identify biological pathways that could be targeted through exercise, weight management, treatment of chronic disease, or other interventions. The study also underscores the need for longitudinal research capable of separating cause from consequence and for standardized testing that can connect laboratory signals with meaningful improvements in daily life.

For now, the review places a spotlight on the immune system as a possible contributor to the physical changes associated with later life. Its focus on CRP, hs-CRP, IL-6, IL-10, and TNF-α reflects the growing recognition that aging is not simply the result of muscles becoming weaker, but of interconnected changes across the body. Understanding how these inflammatory signals relate to mobility could help scientists develop more precise strategies for preserving independence—while reminding clinicians and the public that a blood test is most informative when interpreted together with a person’s functional ability, medical history, and lived environment.

Subject of Research: The relationship between inflammatory biomarkers and physical performance in community-dwelling older adults.

Article Title: What is the impact of CRP, hs-CRP, IL-6, IL-10, and TNFα in physical performance in community-dwelling older adults: a systematic review.

Article References: Boshnjaku, A., Obërtinca, R., Hoxha, M. et al. What is the impact of CRP, hs-CRP, IL-6, IL-10, and TNFα in physical performance in community-dwelling older adults: a systematic review. BMC Geriatrics (2026). https://doi.org/10.1186/s12877-026-08080-8

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08080-8

Keywords: aging, older adults, inflammation, CRP, hs-CRP, IL-6, IL-10, TNF-α, physical performance, inflammaging, systematic review

Chronic pain is often treated as a medical problem that can be measured with scales, prescriptions, and clinical guidelines. For older adults, however, the experience of pain is also shaped by mobility, memory, sleep, mood, independence, and the ability to communicate with health professionals. A new study published in BMC Geriatrics places that lived experience at the center of the discussion, examining how older adults perceive chronic pain management in primary care settings.

The article, authored by P. Gopal, A. Kagarmanova, E. Staab and colleagues, focuses on a point where many long-term health decisions are made: the primary care clinic. Primary care clinicians are often the first professionals to evaluate persistent pain and the people most likely to coordinate treatment over months or years. This makes the setting especially important for older patients, who may be managing several chronic diseases and taking multiple medications at the same time.

Chronic pain is generally defined as pain that persists or recurs for longer than the expected period of tissue healing, commonly described as three months or more. It may arise from osteoarthritis, neuropathy, spinal disorders, previous injuries, cancer, or several conditions acting together. Unlike acute pain, which can serve as a warning signal, chronic pain involves complex changes in the nervous system. Repeated signals can increase the sensitivity of pain pathways, a process known as central sensitization, meaning that pain may continue even after the original injury has stabilized.

For older adults, treating this type of pain is rarely a matter of simply choosing a stronger drug. Age-related changes in kidney and liver function can alter how medicines are absorbed, processed, and eliminated. This can increase the risk of side effects from opioids, sedatives, anti-inflammatory drugs, and other treatments. At the same time, many older patients live with hypertension, heart disease, diabetes, dementia, or depression, conditions that can influence both the perception of pain and the safety of available therapies.

The study’s focus on perceptions is scientifically significant because clinical success cannot be judged only by changes in a numerical pain score. Two people who report the same intensity on a ten-point scale may have very different levels of disability, fear, sleep disruption, or confidence in their treatment. Older adults may value the ability to walk to the shops, sleep through the night, remain socially active, or avoid dependence on family members more than achieving complete elimination of pain. Understanding these priorities can help clinicians define treatment goals that are meaningful in everyday life.

Primary care also presents a distinctive communication challenge. Appointments may be brief, while chronic pain is influenced by physical, psychological, and social factors that require time to explain. Some patients may hesitate to report pain because they fear being dismissed, appearing demanding, or being prescribed medications they do not want. Others may assume that pain is an unavoidable part of aging. When these assumptions remain unspoken, clinicians can underestimate the burden of pain or recommend plans that patients cannot realistically follow.

A patient-centered approach attempts to address this gap by combining clinical evidence with the individual’s preferences, circumstances, and goals. In practice, that may involve medication review, physical therapy, exercise adapted to ability, occupational strategies, psychological support, sleep interventions, and education about pain biology. The technical principle is multimodal care: different treatments target different mechanisms and consequences of pain, potentially reducing reliance on any single intervention. For older adults, coordinated care can also help identify harmful drug interactions and prevent avoidable loss of function.

The research is arriving as health systems confront a rapidly aging population and growing demand for long-term pain care. Chronic pain affects quality of life, physical activity, and healthcare use, yet treatment remains inconsistent across communities. Access to physiotherapy, behavioral health services, specialist pain clinics, and transportation can vary sharply. These structural factors matter because a treatment plan may be clinically sound but ineffective if a patient cannot afford it, reach appointments, understand the instructions, or obtain help at home.

By examining older adults’ views, the paper contributes to a broader shift in pain research: away from treating patients as passive recipients of medical decisions and toward recognizing them as experts in their own daily experience. Their perspectives can reveal whether treatment goals are understandable, whether risks are being communicated clearly, and whether care plans fit real lives. Such information may help primary care teams design more responsive conversations about benefits, harms, uncertainty, and acceptable trade-offs.

The publication does not make the patient’s voice a decorative addition to pain medicine; it treats that voice as evidence relevant to clinical quality. As the medical community searches for safer and more individualized ways to manage chronic pain, the central question is increasingly practical: does the treatment help an older person live better, function more safely, and retain control over daily life? The study by Gopal, Kagarmanova, Staab and colleagues brings that question into primary care, where many of the most important decisions about persistent pain are made.

Subject of Research: Older adults’ perceptions of chronic pain management in primary care settings

Article Title: Perceptions of older adults on chronic pain management in primary care settings

Article References: Gopal, P., Kagarmanova, A., Staab, E. et al. “Perceptions of older adults on chronic pain management in primary care settings.” BMC Geriatrics (2026). https://doi.org/10.1186/s12877-026-08000-w

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08000-w

Keywords: Older adults, chronic pain, pain management, primary care, patient perspectives, geriatrics

Alzheimer’s disease may be leaving a more precise anatomical signature in the brain than scientists once realized. A new study published in Translational Psychiatry investigates regional changes in the fine structure of brain tissue immediately beneath the cerebral cortex, known as the juxtacortical region, and links those changes to patterns of gene expression associated with neurodegeneration. The work, led by J. Zhang, L. Sun, X. Yang and colleagues, offers a combined view of Alzheimer’s biology that connects what can be detected through brain imaging with the molecular programs active inside vulnerable neural tissue.

The juxtacortical zone is a narrow but biologically important interface. It lies directly beneath the cortex, the outer layer responsible for functions including memory, language, perception and decision-making. Although much Alzheimer’s research has focused on cortical thinning, large-scale tissue loss and abnormalities in deeper brain structures, the tissue bordering the cortex may reveal earlier or more regionally specific changes. Its organization includes densely packed axons, dendrites, neurons, glial cells and blood vessels, all of which can be affected as the disease progresses. Subtle disruption in this area could therefore provide clues before dramatic anatomical damage becomes visible.

The study’s central idea is that Alzheimer’s disease does not alter every brain region in the same way. Instead, neurodegeneration follows a complex geography shaped by cellular composition, connectivity, metabolism and genetic vulnerability. By examining regional juxtacortical microstructural changes, the researchers seek to move beyond a simple question of whether tissue has shrunk. Microstructure refers to the organization of brain components at scales smaller than conventional anatomical imaging can directly resolve. Variations in water diffusion, tissue organization and local architecture can serve as indirect markers of changes to axons, membranes, extracellular space and other microscopic features.

This regional perspective matters because the same imaging signal can arise from different biological processes. A change in tissue organization may reflect loss of neuronal connections, damage to myelinated fibers, altered glial activity, inflammation or shifts in the balance of cellular compartments. Imaging alone can reveal where abnormalities are concentrated, but it cannot always explain why they occur. The researchers therefore paired their investigation of juxtacortical structure with gene-expression information, creating a bridge between regional anatomy and molecular biology. That combination can help identify which biological pathways may underlie the imaging patterns seen in Alzheimer’s disease.

Gene expression describes the activity of genes within cells and tissues: which genetic instructions are being read, and at what levels. In the Alzheimer’s brain, these molecular signatures can point toward processes such as synaptic dysfunction, immune activation, impaired energy production, protein handling and cellular stress. Mapping gene-expression patterns onto regions showing microstructural alterations may reveal whether vulnerable areas share particular molecular characteristics. It may also help distinguish tissue changes related directly to neurodegeneration from those associated with aging or general brain atrophy. The result is a more layered portrait of disease, linking microscopic organization to the biological machinery that maintains it.

The findings described by the paper’s title suggest that these two forms of evidence—regional microstructure and gene activity—provide complementary insights into Alzheimer’s pathology. Rather than treating the brain as a uniform organ undergoing gradual damage, the research emphasizes a mosaic of vulnerability. Some areas may show distinctive structural disruption alongside gene-expression profiles associated with neuronal injury or altered support-cell function, while other regions may be relatively resilient. Such differences could help explain why symptoms vary between individuals and why memory, language, attention and other abilities can deteriorate along different trajectories.

The work could also influence how scientists think about biomarkers. A biomarker is a measurable biological feature that helps indicate disease presence, progression or response to treatment. Traditional markers of Alzheimer’s include abnormal amyloid and tau proteins, brain volume loss and changes in metabolism. Juxtacortical microstructural measures, especially when interpreted alongside molecular data, could eventually add regional detail to this toolkit. They might help researchers identify tissue at risk, track the spread of degeneration or evaluate whether an experimental therapy is protecting neural architecture even before clinical improvement becomes obvious.

However, the study should not be interpreted as proof that a single imaging signature can diagnose Alzheimer’s disease or predict an individual’s future with certainty. Microstructural measurements are indirect, and gene-expression data often come from specialized datasets that may not capture every cell type or every stage of disease. Differences in age, disease severity, medication, vascular health and individual brain organization can also influence results. The strength of the approach lies not in one isolated measurement, but in the convergence of regional imaging and molecular evidence. Together, these methods can generate testable hypotheses about how and where neurodegeneration unfolds.

The broader message is that Alzheimer’s research is moving toward increasingly integrated maps of the human brain. The study by Zhang, Sun, Yang and colleagues presents the juxtacortical region as a potentially informative frontier, where microscopic tissue organization and gene regulation intersect. If future research confirms these relationships in larger and more diverse groups, the approach could sharpen disease staging and improve the design of targeted therapies. For now, the findings add weight to a crucial principle in neuroscience: understanding Alzheimer’s requires knowing not only which brain regions are damaged, but also how their cellular architecture and molecular identity make them vulnerable.

Subject of Research: Regional juxtacortical microstructural changes and gene expression in Alzheimer’s disease

Article Title: Regional juxtacortical microstructural changes and gene expression provide insights into neurodegeneration in Alzheimer’s disease

Article References: Zhang, J., Sun, L., Yang, X. et al. “Regional juxtacortical microstructural changes and gene expression provide insights into neurodegeneration in Alzheimer’s disease.” Translational Psychiatry (2026). https://doi.org/10.1038/s41398-026-04292-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04292-z

Keywords: Alzheimer’s disease, neurodegeneration, juxtacortical microstructure, gene expression, brain imaging, neuroscience, biomarkers, translational psychiatry

Bentham Science Launches Two New Journals to Accelerate Research in Wireless Communications and Engineering

Bentham Science Publishers has announced the launch of two new peer-reviewed journals designed to capture the rapid transformation of modern technology: Wireless and Communication Letters and Current Engineering Letters and Reviews. Both publications are now open for manuscript submissions, offering researchers an international platform to share emerging discoveries in communication systems, engineering technologies, and interdisciplinary innovation. The launches arrive as advances in artificial intelligence, sixth-generation wireless networks, satellite systems, advanced materials, and sustainable engineering continue to reshape scientific research and industrial development.

Wireless and Communication Letters is focused on the technologies that enable today’s increasingly connected world. The journal will publish original letters, full-length research articles, comprehensive reviews, mini-reviews, and guest-edited thematic issues addressing both theoretical developments and practical applications. Its scope covers the complete communication chain, from antennas and radio-frequency hardware to signal processing, network architecture, cybersecurity, and intelligent software. By emphasizing the efficient dissemination of research, the journal aims to provide a rapid channel for findings that could influence the next generation of wireless infrastructure.

The technical challenges addressed by the journal are central to the future of digital connectivity. Fifth-generation networks have already introduced high-speed mobile broadband, ultra-reliable low-latency communication, and massive machine-type connectivity, but researchers are now investigating 6G systems capable of supporting even greater data rates, extremely precise sensing, and seamless integration with artificial intelligence. These systems may combine terahertz frequencies, reconfigurable intelligent surfaces, distributed antennas, edge computing, and advanced machine-learning algorithms. Such technologies require new approaches to spectrum allocation, energy efficiency, network coordination, and data security.

The journal also welcomes research on the Internet of Things and machine-to-machine communication, areas in which billions of sensors and devices are expected to exchange data with minimal human intervention. In these environments, communication protocols must operate reliably despite limited power, unpredictable radio conditions, and enormous numbers of connected nodes. Research into low-power wide-area networks, intelligent scheduling, network virtualization, and secure device authentication could help support applications ranging from industrial automation and smart cities to remote healthcare and environmental monitoring.

A further component of the journal’s scope involves the physical science of communication. Antenna design, electromagnetic propagation, microwave engineering, optical links, and satellite communication determine how information travels through real environments. Engineers must account for obstacles, atmospheric conditions, interference, polarization, bandwidth limitations, and the movement of users or spacecraft. Developments in compact antennas, beamforming, optical wireless communication, and satellite-terrestrial integration could improve connectivity in rural regions, disaster zones, transportation systems, and future space missions.

Wireless and Communication Letters is led by Editor-in-Chief Dr. Nasimuddin of the Antenna and Optical Department at the Institute for Infocomm Research in Singapore. Supported by an international editorial board, the journal states that it will apply a rigorous and objective peer-review process. This is particularly important in a field where theoretical claims must often be tested through simulations, prototypes, channel measurements, or performance comparisons. Research involving modulation, coding, information theory, cognitive radio, software-defined networking, artificial intelligence, privacy, and communication protocols will be considered within the journal’s broad technological remit.

Alongside the communications title, Bentham Science has introduced Current Engineering Letters and Reviews, an interdisciplinary journal intended to connect research across the full spectrum of engineering sciences. Announced on 3 August 2026, the journal will publish research articles, short communications, comprehensive reviews, mini-reviews, and thematic issues. Its mission is to bring together discoveries that are often separated into specialist fields, reflecting the reality that many modern technologies emerge from collaboration among mechanical, electrical, materials, chemical, biomedical, environmental, and computer engineers.

The new engineering journal will cover aerospace, civil, structural, transportation, manufacturing, energy, robotics, automation, nanotechnology, artificial intelligence, and digital engineering. It will also address sustainable engineering, renewable energy systems, smart materials, advanced manufacturing, and biomedical technologies. These subjects are increasingly connected: an electric vehicle, for example, depends simultaneously on materials science, power electronics, software, communications, manufacturing, and transportation engineering. An interdisciplinary publication can provide a forum for examining such systems as integrated technological platforms rather than isolated components.

The scientific importance of this approach is becoming more visible as engineers confront challenges involving climate change, resource efficiency, resilient infrastructure, and automation. Renewable energy systems require improved storage, power conversion, and grid management; smart materials can respond to changes in temperature, pressure, or electromagnetic fields; and artificial intelligence can optimize industrial processes by identifying patterns in large streams of sensor data. At the same time, engineering research must demonstrate reliability, scalability, safety, and economic feasibility if laboratory innovations are to produce measurable benefits in society and industry.

Both journals invite contributions from researchers, engineers, scientists, academics, and industry professionals worldwide. Bentham Science says that information about open-access policies, article processing charges, waiver eligibility, editorial policies, and complaints and appeals procedures is available through the respective journal websites. With their emphasis on rapid communication, technical rigor, and interdisciplinary exchange, the two publications seek to become new hubs for research at the intersection of connectivity, intelligent systems, sustainable technology, and engineering innovation.

Subject of Research: Wireless communications, communication engineering, interdisciplinary engineering research, emerging technologies, artificial intelligence, sustainable engineering, and advanced technological systems.

Article Title: Bentham Science Launches Two New Journals to Accelerate Research in Wireless Communications and Engineering

News Publication Date: 3 August 2026 (for the announcement of Current Engineering Letters and Reviews; no publication date is provided for Wireless and Communication Letters).

Keywords

Wireless communications, 5G, 6G, Internet of Things, satellite communications, antenna design, signal processing, artificial intelligence, engineering research, sustainable engineering, robotics, renewable energy, smart materials, advanced manufacturing.

A new study suggests that deep brain stimulation may do more than control movement disorders: it could also help repair social behavior disrupted by pain experienced early in life. In research published in Translational Psychiatry, Wan, Du, Yang and colleagues report that stimulating the brain’s anterior cingulate cortex alleviated social deficits associated with early-life pain. The proposed mechanism is a restoration of the balance between excitatory and inhibitory neural signals, a fundamental process that determines how brain circuits respond, adapt and communicate.

Early-life pain has effects that can extend far beyond the moment of injury or medical treatment. During development, the nervous system is rapidly building connections, refining sensory pathways and establishing the networks that support emotion and social behavior. Excessive or poorly regulated pain signals during this period may alter that process. Instead of remaining confined to pain-processing circuits, these changes can influence stress responses, emotional regulation and the ability to interact with other individuals later in life.

The anterior cingulate cortex, or ACC, is particularly important in this story. Located in the frontal region of the brain, it helps integrate emotional information with attention, motivation and decision-making. It is also involved in processing the unpleasantness of pain and in evaluating social experiences. Because the ACC sits at the intersection of pain, emotion and social behavior, disturbances in its activity could provide a neural explanation for why early-life pain is linked to later difficulties with social interaction.

At the cellular level, the brain depends on a delicate equilibrium between excitation and inhibition. Excitatory neurons generally increase the likelihood that neighboring cells will fire, while inhibitory neurons suppress or constrain that activity. This excitatory/inhibitory, or E/I, balance allows neural circuits to remain flexible without becoming either silent or excessively active. If excitation dominates, networks may become unstable and hypersensitive; if inhibition dominates, communication and behavioral responses may be weakened. The study connects social deficits after early-life pain with disruption of this balance in the ACC.

Deep brain stimulation offers a way to influence such malfunctioning circuits directly. The technique uses electrical pulses delivered through precisely positioned electrodes to modify activity in targeted brain regions. Although DBS is best known clinically for treating Parkinson’s disease, essential tremor and several other neurological conditions, researchers are increasingly investigating whether it can reshape circuits involved in mood, motivation and social behavior. The new findings place the ACC among the brain regions that may be responsive to this approach.

According to the study, stimulation of the ACC improved social abnormalities linked to early-life pain while also normalizing indicators of excitatory and inhibitory signaling. This is important because it suggests that the behavioral improvement was not simply a generalized effect of activating the brain. Instead, the intervention may have acted on a specific circuit-level disturbance. By bringing opposing neural forces back toward equilibrium, DBS could make the ACC more capable of processing social information and generating appropriate responses.

The result also highlights a shift in how scientists understand the consequences of pain during development. Pain is often treated as a temporary sensory event, but developing neural systems can interpret repeated or intense pain as an organizing signal. That signal may alter synaptic strength, neuronal excitability and communication between brain regions. Over time, these changes could become embedded in circuits that regulate social engagement. The study’s emphasis on E/I balance suggests that developmental pain may produce lasting behavioral effects through measurable changes in network physiology rather than through an unexplained psychological process.

The findings are likely to attract attention because social deficits are difficult to treat and can appear across many neurological and psychiatric conditions. However, DBS is an invasive therapy involving neurosurgical implantation, and the study does not mean that the treatment is ready for routine use in people affected by early-life pain. Translating a circuit-level discovery into a safe human therapy requires extensive work, including confirmation in independent models, determination of the most effective stimulation parameters and careful assessment of possible side effects. The ACC is involved in many functions, so altering its activity could influence emotion, attention or pain perception in unwanted ways.

Even with those limitations, the research offers a potentially powerful framework for future therapies. If social difficulties can be linked to a specific imbalance between excitation and inhibition, treatments might eventually be designed to correct that imbalance with greater precision. DBS is only one possibility. Noninvasive stimulation, pharmacological treatments that selectively influence inhibitory or excitatory signaling, and therapies combining behavioral training with neuromodulation could also emerge from the same biological insight.

The study’s central message is that the developing brain may retain a capacity for repair, even after early adverse experiences have changed its circuitry. By targeting the ACC and restoring the neural balance that supports its function, deep brain stimulation improved social behavior in the reported research. The work does not erase the complexity of developmental pain, but it identifies a concrete biological pathway connecting early injury, altered brain networks and later social difficulties. That connection could help move the field closer to treatments that address not only pain itself, but also the long-term social consequences it can leave behind.

Subject of Research: Deep brain stimulation, early-life pain, social deficits, and excitatory/inhibitory balance in the anterior cingulate cortex

Article Title: Deep brain stimulation ameliorates social deficits from early-life pain by restoring excitatory/inhibitory balance in the anterior cingulate cortex

Article References: Wan, X., Du, T., Yang, D. et al. Deep brain stimulation ameliorates social deficits from early-life pain by restoring excitatory/inhibitory balance in the anterior cingulate cortex. Transl Psychiatry (2026). https://doi.org/10.1038/s41398-026-04311-z

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41398-026-04311-z

Keywords: deep brain stimulation, early-life pain, social deficits, anterior cingulate cortex, excitatory/inhibitory balance, neuroscience, brain stimulation, developmental pain, social behavior

A new study is challenging one of the most comforting assumptions in urban climate design: that adding vegetation to dense cities always makes hot weather safer. Research published in npj Urban Sustainability reports that compact, high-rise urban forms can amplify humid heat risks associated with vegetation transpiration—a process usually considered an essential cooling service. The finding does not suggest that trees and plants should be removed from cities. Instead, it reveals that the success of green infrastructure depends heavily on building geometry, airflow, humidity, and the way heat and moisture move through the urban atmosphere.

Vegetation transpiration occurs when plants release water vapor through microscopic openings in their leaves. This process consumes energy and can lower leaf and surrounding air temperatures, much like evaporation from human skin. In a well-ventilated environment, the added moisture may be dispersed efficiently, allowing evaporative cooling to provide a net thermal benefit. But in tightly packed high-rise districts, the same moisture can become trapped between buildings. The result is a more humid microclimate in which the body’s ability to cool itself through sweating is weakened.

That distinction matters because humid heat is more dangerous than air temperature alone suggests. The human body relies on evaporation to transfer heat away from the skin. When atmospheric moisture is already high, sweat evaporates more slowly, forcing the body to work harder to maintain a stable internal temperature. Heat-stress indicators such as wet-bulb temperature and the Wet-Bulb Globe Temperature account for this interaction between heat and humidity. A neighborhood with slightly lower temperatures but substantially higher humidity can therefore feel more oppressive—and pose greater health risks—than a drier location with hotter air.

The study focuses on the urban “canyon” effect created by tall buildings arranged close together. These structures can obstruct wind, reduce the exchange of air with the atmosphere above, and alter the amount of sunlight reaching streets and façades. When vegetation in such spaces transpires, the released water vapor may accumulate rather than disperse. The compact geometry can also create complex circulation patterns, with warm and moist air repeatedly moving through pedestrian-level spaces. In this setting, greenery may cool surfaces while simultaneously increasing the moisture burden experienced by people outdoors.

This is a crucial refinement of the popular idea that urban greening is universally beneficial. Plants perform several valuable functions: they provide shade, intercept solar radiation, reduce surface temperatures, store carbon, and improve the visual and psychological quality of public space. Yet their cooling performance is not fixed. It changes with species, soil moisture, canopy density, irrigation, wind conditions, building height, street width, and background humidity. The new research emphasizes that these factors must be evaluated together rather than treating vegetation as an isolated solution to urban heat.

The implications are particularly significant for rapidly growing cities where vertical development is being used to accommodate rising populations. High-rise construction can reduce land consumption, but dense towers may produce localized atmospheric conditions that differ dramatically from those in surrounding neighborhoods. A cooling strategy designed for an open suburban street may behave differently in a narrow urban canyon surrounded by tall façades. Planners could therefore face a difficult balancing act: maximizing shade and ecological benefits without creating stagnant pockets where moisture and heat combine into dangerous conditions.

The findings also raise questions about how cities measure the success of climate adaptation projects. A street may record a lower surface temperature after trees are planted, yet still expose pedestrians to greater physiological stress if humidity increases and air movement declines. This means future assessments should include multiple variables, including air temperature, relative humidity, wind speed, radiant heat, and human thermal response. Satellite observations and conventional weather stations may not fully capture conditions at street level, where building walls, tree canopies, pavement, and human activity interact within a few meters.

The research is likely to intensify debate over “smart” urban greening rather than green infrastructure in general. Possible responses include selecting vegetation according to local humidity and wind conditions, designing wider or better-connected ventilation corridors, combining trees with reflective or permeable surfaces, and ensuring that shaded areas do not become poorly ventilated enclosures. Building orientation and spacing may be as important as the number of trees planted. Irrigation practices could also matter, since additional water supplied to vegetation may increase transpiration during precisely the periods when atmospheric moisture is already high.

For residents, the message is both cautionary and practical. A leafy street can still be healthier than an exposed one, particularly when shade reduces direct solar radiation. But during extreme heat, people should not assume that every green space offers the same level of protection. Dense, humid, windless areas may require additional measures such as cooling centers, drinking-water access, timed outdoor activities, and heat alerts that account for humidity. The study’s central contribution is to show that urban climate risk is not determined by temperature alone—or by the presence of greenery alone—but by the interaction between city form, plant physiology, and human vulnerability.

As climate change increases the frequency and intensity of heat extremes, these interactions could become more consequential. The research presents cities with a deceptively simple lesson: cooling the urban environment is not just a matter of adding more plants. It requires understanding where the water released by vegetation goes, how buildings control its movement, and how the resulting air feels to a human body. In the race to make cities greener, the next generation of design may need to be equally focused on keeping them breathable.

Subject of Research: The relationship between compact high-rise urban form, vegetation transpiration, humidity, and humid heat risk.

Article Title: Urban high-rise compact form amplifies humid heat risk from vegetation transpiration.

Article References: Zhang, Y., Yang, K., Zhu, Y. et al. “Urban high-rise compact form amplifies humid heat risk from vegetation transpiration.” npj Urban Sustainability (2026). https://doi.org/10.1038/s42949-026-00459-1

Image Credits: AI Generated

DOI: 10.1038/s42949-026-00459-1

Long-term care residents moving from a nursing facility to an emergency department enter one of the most complex transitions in modern healthcare. The journey may begin with a sudden change in consciousness, breathing, mobility, pain, or behavior, but it quickly becomes a transfer of information, responsibility, and risk between institutions. A new qualitative study published in BMC Geriatrics examines how this cross-setting transition is experienced by the people involved, highlighting a vulnerable point in the healthcare system that is often treated as a routine logistical event.

The study, led by PC Hsu, LY.A. Chen, and YC Chen and colleagues, focuses on residents of long-term care facilities who are transferred to emergency departments. Unlike quantitative research, which typically measures outcomes such as admission rates, waiting times, or mortality, qualitative research investigates how individuals interpret and experience a process. Through this approach, researchers can identify communication breakdowns, conflicting expectations, emotional pressures, and practical barriers that may not appear in hospital databases.

For older adults living in long-term care, an emergency transfer can be medically necessary but physically and psychologically destabilizing. Many residents live with multiple chronic conditions, frailty, dementia, sensory impairment, or limited ability to communicate. These characteristics can make it difficult for them to describe symptoms, understand unfamiliar surroundings, or participate directly in decisions. The emergency department, meanwhile, is designed for rapid assessment and acute treatment, not always for the slower, highly individualized care needs of frail older people.

The transition also creates a handover challenge. Clinical information must travel with the resident, including medication lists, allergies, advance-care preferences, baseline cognitive and functional status, recent symptoms, and the reason for transfer. If any of this information is incomplete, delayed, or misunderstood, clinicians may have to reconstruct the patient’s history under intense time pressure. This can lead to duplicated tests, inappropriate medication decisions, delays in treatment, or care plans that fail to reflect the resident’s usual condition.

A central technical issue is the difference between a patient’s baseline and an acute change. A resident with dementia may appear confused in the emergency department even when their behavior is consistent with their usual state. Conversely, a subtle change in alertness or mobility may indicate infection, dehydration, stroke, or another serious condition. Without reliable baseline information from long-term care staff or family members, emergency clinicians may struggle to distinguish chronic impairment from delirium, a sudden disturbance in attention and cognition associated with substantial risks in older adults.

By examining experiences across care settings, the research addresses the concept of continuity of care. Continuity is not simply the transfer of documents; it includes consistency in clinical goals, communication, decision-making, and personal knowledge of the resident. A successful transition requires coordination among long-term care workers, emergency medical services, hospital clinicians, residents, and families. Each group may possess only part of the relevant information, making the quality of interaction between them as important as the technology used to transmit records.

The study’s qualitative design is particularly valuable because transitions are shaped by human factors. Staff may face time constraints, staffing shortages, unclear responsibilities, or different documentation systems. Families may experience anxiety when they are asked to make urgent decisions without a complete explanation of the resident’s condition. Residents may feel disoriented or powerless as they move between unfamiliar environments. Capturing these perspectives can reveal why formal protocols sometimes fail in practice, even when they appear comprehensive on paper.

The findings are relevant to a wider healthcare challenge: populations are aging while medical care is becoming increasingly fragmented. Long-term care facilities and hospitals often operate under separate administrative structures, with different workflows, electronic records, professional cultures, and performance measures. Emergency departments may focus on rapid diagnosis and disposition, whereas long-term care teams emphasize daily function, prevention, and quality of life. The transition between these systems can therefore become a vulnerable interface where important context is lost.

Improving that interface could involve standardized transfer forms, interoperable electronic records, direct clinician-to-clinician communication, clearer escalation pathways, and explicit documentation of a resident’s baseline function and care preferences. Yet the study’s focus on lived experience suggests that technical solutions alone may not be sufficient. Better transitions also depend on mutual understanding, shared accountability, and recognition that a transfer is not an isolated event but a continuum extending from the long-term care facility to the emergency department and back again.

As healthcare systems search for ways to reduce preventable harm among older adults, the experience of cross-setting transitions deserves greater attention. The study by Hsu, Chen, Chen, and colleagues places this often-overlooked process at the center of inquiry. Its subject is not merely how residents are transported, but how information, clinical judgment, dignity, and responsibility move with them. That perspective may help health services design emergency transfers that are safer, more coordinated, and more responsive to the realities of long-term care.

Subject of Research: Cross-setting care transitions of long-term care residents to the emergency department.

Article Title: The experience of cross-setting care transitions of long-term care residents to the emergency department: a qualitative study

Article References: Hsu, PC., Chen, LY.A., Chen, YC. et al. “The experience of cross-setting care transitions of long-term care residents to the emergency department: a qualitative study.” BMC Geriatrics (2026). https://doi.org/10.1186/s12877-026-08059-5

Image Credits: AI Generated

DOI: 10.1186/s12877-026-08059-5

Cancer-associated cachexia, the wasting syndrome that erodes muscle, fat and physical resilience in many people with advanced cancer, has long resisted treatment. Now, researchers at the Korea Advanced Institute of Science and Technology (KAIST) report a preclinical strategy that targets the disorder from an unexpected location: the brainstem. In tumor-bearing mice, an RNA-based therapy designed to silence a neural receptor preserved body weight, muscle mass, fat stores and physical function, while dramatically improving survival even after cachexia had already developed.

The study was conducted by a joint team led by Minho Shong and Jinkuk Kim of KAIST’s Graduate School of Medical Science and Engineering, in collaboration with the KAIST faculty startup THOR Therapeutics. Their approach focuses on the biological circuit formed by growth differentiation factor 15, or GDF15, and its receptor, GFRAL. GDF15 is a signaling protein released in elevated amounts during several disease states, including cancer. When it reaches the hindbrain and binds to GFRAL, it activates neural pathways associated with nausea, appetite suppression and profound metabolic changes.

Cachexia is more complex than ordinary weight loss. Patients can continue losing muscle and body fat even when food intake is adequate, because cancer and the host response to cancer disrupt the systems that regulate energy use, inflammation and tissue maintenance. The resulting decline can weaken immunity, reduce mobility and make chemotherapy more difficult to tolerate. Although the syndrome affects an estimated 50 to 80 percent of people with cancer, available treatments have generally focused on stimulating appetite or providing nutritional support. Such measures may increase food intake temporarily, but they do not necessarily halt the breakdown of muscle or correct the underlying metabolic disturbance.

The KAIST researchers reasoned that the GDF15–GFRAL pathway could act as a central command system for this wasting response. GDF15 produced in the body circulates to the brainstem, where GFRAL is concentrated in a specialized region known as the area postrema and its surrounding neural circuitry. Once activated, this receptor can influence brain networks that control feeding behavior and autonomic metabolism. Rather than attempting to neutralize GDF15 throughout the body, the team chose to disable the receptor itself in the brainstem, preventing the signal from being received.

To accomplish this, the researchers developed antisense oligonucleotides, or ASOs, directed against Gfral messenger RNA. ASOs are short, chemically modified strands of nucleic acid engineered to bind a specific RNA sequence. When an ASO binds its target messenger RNA, cellular enzymes can promote its degradation or interfere with its processing, reducing production of the corresponding protein. In this case, the treatment lowered the supply of GFRAL receptors in the brainstem. The strategy therefore acts at the RNA stage, before the receptor is assembled and displayed on the surface of neural cells.

The experiments were performed in mice carrying tumors and showing established signs of cancer cachexia. This timing is important because many experimental interventions appear effective only when administered before severe wasting begins. According to the researchers, GFRAL silencing after cachexia had progressed substantially reduced the loss of muscle and fat. Treated animals also showed restoration of metabolic functions that had deteriorated during tumor growth, suggesting that the intervention did more than increase appetite. It helped interrupt the physiological program driving the breakdown of energy reserves.

The most striking result involved survival. At approximately day 50, the endpoint used in the study, about 90 percent of the mice receiving the GFRAL-targeting ASO remained alive, compared with roughly 20 percent of untreated tumor-bearing animals. The treated mice retained greater body weight and muscle mass and performed better in measures of muscle function. These findings indicate that cachexia itself can be a major determinant of outcome in cancer-bearing organisms and that blocking its central signaling pathway may provide benefits beyond nutritional improvement.

The work does not yet establish whether the same treatment will be safe or effective in people. GFRAL signaling is involved in the body’s response to circulating stress signals, and manipulating a receptor in the brainstem requires careful assessment of neurological, cardiovascular, gastrointestinal and metabolic effects. Human cancers also vary widely in their production of GDF15, tumor location and inflammatory biology. Nevertheless, the results offer a mechanistically precise alternative to therapies that merely encourage patients to eat. By targeting the receptor rather than broadly suppressing the signaling protein, the ASO approach may eventually be combined with chemotherapy, immunotherapy or other cancer treatments.

The findings, published in Cell Reports Medicine, represent an early step toward translating a brain-directed RNA therapy for cachexia. The researchers plan further preclinical studies, along with development of manufacturing and quality-control systems, with the stated goal of beginning clinical development in cancer patients by 2030. If the biology can be reproduced safely in humans, silencing GFRAL could become an adjunct treatment intended to preserve physical function, extend treatment tolerance and improve survival. For now, however, the evidence remains limited to tumor-bearing mice, and the central challenge will be determining whether a signal that can be switched off experimentally can be controlled with equal precision in patients.

Subject of Research:
An antisense oligonucleotide therapy targeting brainstem GFRAL to treat cancer-associated cachexia in tumor-bearing mice.

Article Title:
Therapeutic Gfral silencing via antisense oligonucleotides ameliorates cancer-associated cachexia and extends survival in tumor-bearing mice

Web References:
https://doi.org/10.1016/j.xcrm.2026.102939

References:
Cell Reports Medicine, published 27 July 2026. DOI: 10.1016/j.xcrm.2026.102939

Image Credits:
KAIST

Keywords:
Cancer cachexia, GFRAL, GDF15, antisense oligonucleotides, RNA therapy, brainstem, muscle wasting, cancer metabolism, preclinical research, KAIST

A common complication of early birth is being thrust into a medical debate that reaches far beyond the neonatal intensive-care unit: how low is too low when a late preterm baby’s blood glucose falls, and what—if anything—does that episode mean years later? A new article in Pediatric Research examines late preterm hypoglycemia through the lens of long-term evidence, highlighting why a seemingly brief metabolic disturbance has become one of neonatology’s most closely watched questions.

Late preterm infants are typically born between 34 weeks and 36 weeks plus six days of gestation. They often appear stronger and more mature than very preterm babies, but their brains, hormone systems and feeding abilities are still developing. After birth, glucose levels can drop as the infant transitions from a constant placental supply to intermittent feeding. Immature glycogen stores, limited fat reserves, difficulty coordinating sucking and swallowing, and illness-related stress can all increase the risk of hypoglycemia.

Glucose is the brain’s primary energy source during early life, making neonatal hypoglycemia biologically concerning. When glucose delivery falls, the brain may initially compensate by using alternative fuels, including lactate and ketone bodies. If the shortage is severe, prolonged or repeatedly missed, however, energy production can become insufficient. This may interfere with neuronal signaling and, in extreme cases, contribute to cellular injury. The challenge is that many affected newborns show no obvious symptoms, while symptomatic infants may display only subtle signs such as jitteriness, poor feeding, lethargy, temperature instability or apnea.

The article by U. Felderhoff-Müser focuses attention on a crucial gap between immediate treatment and long-term certainty. Hospitals commonly screen infants considered vulnerable to hypoglycemia, including late preterm newborns, and intervene with feeding, buccal dextrose gel or intravenous glucose when indicated. These measures are designed to restore glucose quickly and prevent neurological stress. Yet the threshold used to define hypoglycemia is not a universal biological line. It is a clinical value shaped by gestational age, postnatal age, symptoms, measurement method and the balance between avoiding harm and preventing unnecessary intervention.

That uncertainty has made long-term follow-up essential. Researchers have investigated whether neonatal hypoglycemia is associated with later problems involving cognition, executive function, attention, language, motor coordination and school performance. Some studies have reported higher risks after severe, recurrent or prolonged episodes, while others have found limited or inconsistent effects, particularly when low glucose was detected and treated promptly. The differences may reflect more than glucose itself: prematurity, fetal growth restriction, maternal diabetes, infection, respiratory illness and socioeconomic conditions can independently influence neurodevelopment.

This is one reason the evidence remains difficult to interpret. Most long-term studies are observational, meaning researchers cannot randomly assign infants to experience different glucose levels. Instead, they compare children who had hypoglycemia with those who did not, while attempting to account for other medical and social factors. Even sophisticated statistical adjustments may not eliminate hidden confounding. In addition, studies use different definitions of hypoglycemia, different monitoring schedules and different ages or tools for developmental testing, making direct comparisons challenging.

The timing and pattern of low glucose may be as important as the lowest recorded number. A single short episode may carry a different biological significance from repeated episodes or an extended period below a treatment threshold. Continuous glucose monitoring has raised further questions by revealing fluctuations that intermittent heel-stick testing can miss, although sensor accuracy in newborns and the clinical meaning of every detected dip are still being evaluated. The emerging picture is therefore more complex than a simple division between “normal” and “abnormal.”

For clinicians and families, the practical message is not to dismiss hypoglycemia or to assume that every low reading predicts disability. Instead, the long-term evidence supports careful surveillance of infants at risk, rapid confirmation of abnormal results, and treatment strategies that protect the brain without disrupting feeding or exposing babies to unnecessary interventions. Developmental follow-up may be particularly important for infants with severe or recurrent episodes, neurological symptoms, or multiple additional risk factors. Such monitoring can identify difficulties early, when speech, occupational or educational support may have the greatest effect.

The discussion also underscores the need for better research. Future studies will need standardized glucose definitions, precise records of duration and recurrence, improved measurement technologies and follow-up extending into school age and adolescence. Researchers must also distinguish the effects of hypoglycemia from the conditions that caused it and examine outcomes beyond a single global developmental score. Felderhoff-Müser’s review places late preterm hypoglycemia in that broader scientific context: a common neonatal event whose immediate management is well established, but whose long-term consequences still demand careful, nuanced investigation.

Subject of Research: Late preterm hypoglycemia and its long-term neurodevelopmental evidence

Article Title: Late preterm hypoglycemia through the lens of long-term evidence

Article References: Felderhoff-Müser, U. “Late preterm hypoglycemia through the lens of long-term evidence.” Pediatric Research (2026). https://doi.org/10.1038/s41390-026-05316-6

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41390-026-05316-6

Keywords: late preterm infants, neonatal hypoglycemia, blood glucose, neurodevelopment, brain health, newborn care, long-term outcomes